Laura Elst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Elst has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Maarten Albersen
Department of Urology, University Hospitals Leuven, Leuven, Belgium
8 shared publications - Oscar Roberto Brouwer
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital 1 Department of Urology Amsterdam, the Netherlands
4 shared publications Benjamin Ayres
Department of Urology, St.‐George's University Hospitals NHS Foundation Trust London UK
2 shared publications- Hielke Martijn de Vries
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital 1 Department of Urology Amsterdam, the Netherlands
2 shared publications - Kaat Vandermaesen
VIB-KU Leuven, Laboratory of Translational Genetics, Center for Cancer Biology, Leuven, Belgium
2 shared publications - Marija Miletić
Cancer Dynamics Laboratory, Francis Crick Institute, London, UK; Cancer Dynamics Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK; Renal and Skin Units, Royal Marsden NHS Foundation Trust, London, UK
2 shared publications
Latest Publications
- 26 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Preexisting Immunity and hrHPV Status Determine Immunotherapy Response in Advanced Penile Cancer: Biomarkers and Overall Survival in the PERICLES Trial
Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy (RT) in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n = 12) or atezolizumab in combination with RT (n = 20, 33 fractions of 1.5–1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n = 28/31) was performed using bulk RNA sequencing, immunohistochemistry, and multiplex immunofluorescence. Additionally, spatial transcriptomics (n = 9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% [95% confidence interval (CI), 9.1–38.6] and 12.5% (95% CI, 5–31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFNγ and IFNα signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD-1+ T-cell density were associated with nonprogression at 1 year. Increased intratumoral CD8+PD-1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells coexpressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD-1+ T cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.
- 26 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Preexisting Immunity and hrHPV Status Determine Immunotherapy Response in Advanced Penile Cancer: Biomarkers and Overall Survival in the PERICLES Trial
Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy (RT) in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n = 12) or atezolizumab in combination with RT (n = 20, 33 fractions of 1.5–1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n = 28/31) was performed using bulk RNA sequencing, immunohistochemistry, and multiplex immunofluorescence. Additionally, spatial transcriptomics (n = 9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% [95% confidence interval (CI), 9.1–38.6] and 12.5% (95% CI, 5–31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFNγ and IFNα signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD-1+ T-cell density were associated with nonprogression at 1 year. Increased intratumoral CD8+PD-1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells coexpressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD-1+ T cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.
- 3 November 2025
- Published by Wiley in BJU International
- Vol. 137 (1) , 146-153
Local recurrence after glans‐sparing surgery: no impact on penile cancer‐specific survival
Objectives: To assess local recurrence (LR) and its impact on cancer‐specific survival (CSS) in an international multicentric homogeneous cohort of lower‐risk patients with penile squamous cell carcinoma (PSCC) that underwent glans‐sparing surgery (GSS). Patients and Methods: We retrospectively studied patients with PSCC treated with circumcision, wide local excision, glans resurfacing, partial glansectomy and laser ablation, collectively defined as GSS. To understand whether LR itself impacts CSS, patients with lymphatic or systemic disease prior or concurrent with LR were excluded. Predictors of LR and its impact on CSS were assessed using Cox proportional hazard regression and Kaplan–Meier survival analysis, respectively. Results: Across 15 institutions, 550 patients were included. The majority had pathological T1 stage (79%) tumours, reflecting the selection of less invasive tumours for GSS. At a median (interquartile range) follow‐up of 41 (23–63) months, 162 (29%) patients experienced LR. LR did not affect cancer‐specific mortality and 5‐year CSS remained at 99%. Three patients died from penile cancer, none of whom showed a LR during their disease course. The presence of penile intraepithelial neoplasia in the surgical margin was an independent predictor of LR (hazard ratio 2.28, P = 0.02), even after adjusting for additional treatments. Conclusion: Patients undergoing GSS for PSCC demonstrate excellent survival outcomes, despite LR in 29% of men. These findings support the use of GSS as a safe and effective treatment option for patients committed to adequate follow‐up.
- 3 November 2025
- Published by Wiley in BJU International
- Vol. 137 (1) , 146-153
Local recurrence after glans‐sparing surgery: no impact on penile cancer‐specific survival
Objectives: To assess local recurrence (LR) and its impact on cancer‐specific survival (CSS) in an international multicentric homogeneous cohort of lower‐risk patients with penile squamous cell carcinoma (PSCC) that underwent glans‐sparing surgery (GSS). Patients and Methods: We retrospectively studied patients with PSCC treated with circumcision, wide local excision, glans resurfacing, partial glansectomy and laser ablation, collectively defined as GSS. To understand whether LR itself impacts CSS, patients with lymphatic or systemic disease prior or concurrent with LR were excluded. Predictors of LR and its impact on CSS were assessed using Cox proportional hazard regression and Kaplan–Meier survival analysis, respectively. Results: Across 15 institutions, 550 patients were included. The majority had pathological T1 stage (79%) tumours, reflecting the selection of less invasive tumours for GSS. At a median (interquartile range) follow‐up of 41 (23–63) months, 162 (29%) patients experienced LR. LR did not affect cancer‐specific mortality and 5‐year CSS remained at 99%. Three patients died from penile cancer, none of whom showed a LR during their disease course. The presence of penile intraepithelial neoplasia in the surgical margin was an independent predictor of LR (hazard ratio 2.28, P = 0.02), even after adjusting for additional treatments. Conclusion: Patients undergoing GSS for PSCC demonstrate excellent survival outcomes, despite LR in 29% of men. These findings support the use of GSS as a safe and effective treatment option for patients committed to adequate follow‐up.
- 6 August 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (9) , 782-793
The prognostic role of HPV status in penile squamous cell carcinoma: a systematic review and meta-analysis
Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy that can present as either Human papillomavirus (HPV)-associated or HPV-independent. Currently, there is no consensus on the prognostic value of HPV status in PSCC or its role in guiding treatment strategies. Therefore, in this systematic review and meta-analysis we aim to assess the impact of different methods of determining HPV status on cancer specific survival (CSS) and overall survival (OS) in patients with PSCC. Databases including MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched between 1980 and February 2025. Studies were eligible if they assessed HPV status using any method in PSCC patients and reported CSS or OS with a minimum follow-up of two years. Case reports, narrative reviews, expert opinions, and studies reporting less than 50 participants were excluded. Quality of included studies was assessed using the QUIPS tool. A total of 31 studies, published between 2001 and 2024, met the inclusion criteria, all of which were of retrospective design. High risk of bias (RoB) was noted for study attrition, prognostic factor measurement, and study confounding. Sample sizes ranged from 57 to 611 participants (median: 152 participants). HPV-status was assessed through DNA testing in 19 studies and 10 studies used p16 immunohistochemistry (IHC) as a surrogate marker of HPV-driven carcinogenesis. Four studies used both HPV DNA measurements and p16 IHC staining and two articles determined HPV status based on histological subtyping. Median follow-up was 49.9 months (range: 27-107.9 months). We identified 23 studies that reported sufficient data for inclusion in a meta-analysis, encompassing a total of 5291 men with various stages of PSCC. Of these, 1946 (36.8%) had HPV-associated disease. Positive p16 status was associated with improved CSS (HR = 0.40, 95% CI [0.20, 0.80], p = 0.009) and OS (HR = 0.49, 95% CI [0.29, 0.85], p = 0.01) in a pooled cohort of 1266 and 1189 patients respectively. HPV DNA positivity was associated with improved CSS (HR = 0.54, 95% CI [0.35, 0.83], p = 0.005), but not with OS (HR = 0.86 95% CI [0.70, 1.07], p = 0.17). In conclusion, p16 and HPV DNA positivity are associated with improved CSS in patients with PSCC. Positive p16 status was related to better OS, while HPV status based on DNA measurements was not. These findings underscore the prognostic value of p16 and HPV status.
- 6 August 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (9) , 782-793
The prognostic role of HPV status in penile squamous cell carcinoma: a systematic review and meta-analysis
Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy that can present as either Human papillomavirus (HPV)-associated or HPV-independent. Currently, there is no consensus on the prognostic value of HPV status in PSCC or its role in guiding treatment strategies. Therefore, in this systematic review and meta-analysis we aim to assess the impact of different methods of determining HPV status on cancer specific survival (CSS) and overall survival (OS) in patients with PSCC. Databases including MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched between 1980 and February 2025. Studies were eligible if they assessed HPV status using any method in PSCC patients and reported CSS or OS with a minimum follow-up of two years. Case reports, narrative reviews, expert opinions, and studies reporting less than 50 participants were excluded. Quality of included studies was assessed using the QUIPS tool. A total of 31 studies, published between 2001 and 2024, met the inclusion criteria, all of which were of retrospective design. High risk of bias (RoB) was noted for study attrition, prognostic factor measurement, and study confounding. Sample sizes ranged from 57 to 611 participants (median: 152 participants). HPV-status was assessed through DNA testing in 19 studies and 10 studies used p16 immunohistochemistry (IHC) as a surrogate marker of HPV-driven carcinogenesis. Four studies used both HPV DNA measurements and p16 IHC staining and two articles determined HPV status based on histological subtyping. Median follow-up was 49.9 months (range: 27-107.9 months). We identified 23 studies that reported sufficient data for inclusion in a meta-analysis, encompassing a total of 5291 men with various stages of PSCC. Of these, 1946 (36.8%) had HPV-associated disease. Positive p16 status was associated with improved CSS (HR = 0.40, 95% CI [0.20, 0.80], p = 0.009) and OS (HR = 0.49, 95% CI [0.29, 0.85], p = 0.01) in a pooled cohort of 1266 and 1189 patients respectively. HPV DNA positivity was associated with improved CSS (HR = 0.54, 95% CI [0.35, 0.83], p = 0.005), but not with OS (HR = 0.86 95% CI [0.70, 1.07], p = 0.17). In conclusion, p16 and HPV DNA positivity are associated with improved CSS in patients with PSCC. Positive p16 status was related to better OS, while HPV status based on DNA measurements was not. These findings underscore the prognostic value of p16 and HPV status.
- 16 April 2025
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 26 (5) , 367-374
Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine
Opinion statement Penile cancer is a rare but aggressive malignancy, characterized by early lymphatic spread which is the most critical prognostic factor. Treatment options for patients with locally advanced and metastatic disease are limited, primarily relying on cisplatin-based chemotherapy, which is characterized by high toxicity and early resistance. In recent years, there has been a growing interest on translational research exploring the tumor microenvironment, enabling the identification of novel potential therapeutic targets. Emerging preclinical evidence supports the use of immune checkpoint inhibitors, antibody–drug conjugates and novel exploratory therapies targeting myeloid-derived suppressor cells and tumor associated macrophages, as well as their combinations. However, robust phase III trials investigating such therapies are currently lacking. A deeper understanding of the penile cancer immune landscape and the role of specific mutations in carcinogenesis, might lead to the development of novel combination strategies to overcome cisplatin resistance and disease progression, and to a better selection of patients for inclusion in future clinical trials.
- 16 April 2025
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 26 (5) , 367-374
Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine
Opinion statement Penile cancer is a rare but aggressive malignancy, characterized by early lymphatic spread which is the most critical prognostic factor. Treatment options for patients with locally advanced and metastatic disease are limited, primarily relying on cisplatin-based chemotherapy, which is characterized by high toxicity and early resistance. In recent years, there has been a growing interest on translational research exploring the tumor microenvironment, enabling the identification of novel potential therapeutic targets. Emerging preclinical evidence supports the use of immune checkpoint inhibitors, antibody–drug conjugates and novel exploratory therapies targeting myeloid-derived suppressor cells and tumor associated macrophages, as well as their combinations. However, robust phase III trials investigating such therapies are currently lacking. A deeper understanding of the penile cancer immune landscape and the role of specific mutations in carcinogenesis, might lead to the development of novel combination strategies to overcome cisplatin resistance and disease progression, and to a better selection of patients for inclusion in future clinical trials.
- 22 November 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (1) , 102275
Complex Decision Making for Individual Patients With Penile Cancer: Benchmarking Divergent Practices in European High-Volume Reference Centers: Results From eUROGEN Survey
- 22 November 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (1) , 102275
Complex Decision Making for Individual Patients With Penile Cancer: Benchmarking Divergent Practices in European High-Volume Reference Centers: Results From eUROGEN Survey
- 19 July 2024
- Published by Wiley in BJU International
- Vol. 134 (6) , 881-889
Penile intraepithelial neoplasia incidence, clinical classification, microenvironment and implications for imiquimod treatment
Objectives: To provide an outline of the existing data on penile intraepithelial neoplasia (PeIN), as well as a narrative review on imiquimod (IQ; a toll‐like receptor 7 agonist) treatment and immune microenvironment markers that may predict response to treatment. Methods: A narrative review of the literature from 2000 to the present was conducted on PubMed, and we describe the most relevant data and cross references. Results: The incidence of PeIN is increasing. Local therapy with IQ may offer an easy applicable treatment with complete response rates of up to 63% but can be associated with considerable side‐effects. There is no conclusive data on the optimal treatment schedule for PeIN, but evaluation of treatment results for other human papillomavirus‐related pre‐malignancies suggest three times a week for a duration up to 16 weeks. There are no published studies concerning the PeIN immune microenvironment. However, findings from the few studies on penile cancer and pre‐cancerous vulvar and cervical lesions imply that specific immune cell subpopulations can serve as future predictors for successful immunomodulation treatments such as IQ. Conclusions: Overall, limited data are available on IQ treatment for PeIN and no published data exists on the PeIN immune microenvironment. Further translational studies are warranted to gain more understanding on the pathophysiology of PeIN and potential predictors of progression and of response to topical treatments.
- 19 July 2024
- Published by Wiley in BJU International
- Vol. 134 (6) , 881-889
Penile intraepithelial neoplasia incidence, clinical classification, microenvironment and implications for imiquimod treatment
Objectives: To provide an outline of the existing data on penile intraepithelial neoplasia (PeIN), as well as a narrative review on imiquimod (IQ; a toll‐like receptor 7 agonist) treatment and immune microenvironment markers that may predict response to treatment. Methods: A narrative review of the literature from 2000 to the present was conducted on PubMed, and we describe the most relevant data and cross references. Results: The incidence of PeIN is increasing. Local therapy with IQ may offer an easy applicable treatment with complete response rates of up to 63% but can be associated with considerable side‐effects. There is no conclusive data on the optimal treatment schedule for PeIN, but evaluation of treatment results for other human papillomavirus‐related pre‐malignancies suggest three times a week for a duration up to 16 weeks. There are no published studies concerning the PeIN immune microenvironment. However, findings from the few studies on penile cancer and pre‐cancerous vulvar and cervical lesions imply that specific immune cell subpopulations can serve as future predictors for successful immunomodulation treatments such as IQ. Conclusions: Overall, limited data are available on IQ treatment for PeIN and no published data exists on the PeIN immune microenvironment. Further translational studies are warranted to gain more understanding on the pathophysiology of PeIN and potential predictors of progression and of response to topical treatments.
- 15 March 2024
- Published by Elsevier in European Urology Oncology
- Vol. 7 (5) , 1155
Reply to Marco Bandini, Andrea Salonia, and Francesco Montorsi’s Letter to the Editor re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.005
- 15 March 2024
- Published by Elsevier in European Urology Oncology
- Vol. 7 (5) , 1155
Reply to Marco Bandini, Andrea Salonia, and Francesco Montorsi’s Letter to the Editor re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.005
- Open Access
- 30 August 2023
- Published by Wiley in BJUI Compass
- Vol. 5 (1) , 166-169
International case series of metastasis to penis
Penile metastases are rare, with about 400 reported via case reports or small series. Under such circumstances coherent data about their behaviour may not be possible given vagaries of publication. For instance, one published meta‐analysis has proposed that malignant priapism contributes to worse survival, but this may be due to selection bias in published reports. We sought to evaluate clinical characteristics associated with survival in an international cohort of patients with metastases to the penis treated in major genitourinary cancer programmes.
- 30 August 2023
- Published by Wiley in BJUI Compass
- Vol. 5 (1) , 166-169
Open AccessInternational case series of metastasis to penis
Penile metastases are rare, with about 400 reported via case reports or small series. Under such circumstances coherent data about their behaviour may not be possible given vagaries of publication. For instance, one published meta‐analysis has proposed that malignant priapism contributes to worse survival, but this may be due to selection bias in published reports. We sought to evaluate clinical characteristics associated with survival in an international cohort of patients with metastases to the penis treated in major genitourinary cancer programmes.